Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M

ARTIVION, INC.

2022-FY EPS reported -$0.48 revenue$313,789,000

Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.
GAAP net income $2.2M ($0.05 EPS) vs net loss $20.1M ($0.51); non-GAAP $4.2M ($0.10).
FY2022 revenue $313.8M (+5% GAAP, +9% CC); net loss $19.2M ($0.48) vs $14.8M ($0.38) in 2021.
Received CE mark for BioGlue under EU MDR in Q4 2022.
2023 guidance: CC revenue growth 8-12%, revenue $331M-$343M, adjusted EBITDA >$50M (+20%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARTIVION, INC. reported the fourth quarter ended December 31, 2022 results: revenue $79.4 million, net income $2.2 million, EPS $0.05 per fully diluted common share. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2022
Revenue: $79.4 million
Net income: $2.2 million
EPS: $0.05 per fully diluted common share
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Total revenues for the fourth quarter of 2022 were $79.4 million, flat on a GAAP basis and an increase of 5% on a non-GAAP constant currency basis, both compared to the fourth quarter of 2021. Net income for the fourth quarter of 2022 was $2.2 million, or $0.05 per fully diluted common share, compared to net loss of ($20.1) million, or ($0.51) per fully diluted common share for the fourth quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARTIVION, INC. reported the full year ended December 31, 2022 results: revenue $313.8 million, net income ($19.2) million, EPS ($0.48) per fully diluted common share. Guidance reaffirmed.

Period: the full year ended December 31, 2022
Revenue: $313.8 million
Net income: ($19.2) million
EPS: ($0.48) per fully diluted common share
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Total revenues for 2022 were $313.8 million, reflecting an increase of 5% on a GAAP basis and 9% on a non-GAAP constant currency basis compared to the full year of 2021. Net loss for 2022 was ($19.2) million, or ($0.48) per fully diluted common share, compared to net loss of ($14.8) million, or ($0.38) per fully diluted common share for the full year of 2021.

View on SEC.gov

Browse all earnings releases →

ARTIVION, INC. filing history →

Source: SEC EDGAR

accession 0000784199-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.